Equipped with Small, Medium, and Large-Scale Production Lines
Providing Client-Centric Services
On September 4, ST Pharm held a completion ceremony for its 2nd Oligo Building at the Banwol Campus in Ansan, Gyeonggi Province, establishing a foundation for its leap toward becoming the world’s number one CDMO (Contract Development and Manufacturing Organization) for oligonucleotide nucleic acids.
Kang Jungseok, Chairman of the Dong-A Socio Committee (fourth from the left in the photo), and the executive team of Dong-A Socio Group attended the commemorative ceremony for the completion of ST Pharm's 2nd Oligo Building, adding prestige to the event. (From the left in the photo) Im Jinseok, Head of Production at ST Pharm; Kim Minyoung, President of Dong-A Socio Holdings; Sung Mooje, President of ST Pharm; Kang Jungseok, Chairman of the Dong-A Socio Committee; Jung Jaehoon, President of Dong-A ST; Baek Sanghwan, President of Dong-A Pharmaceutical; and Park Yoon, President of Aven General Construction, are posing for a commemorative photo. ST Pharm Photo by ST Pharm
The 2nd Oligo Building was constructed as a proactive response to the continued growth of the oligonucleotide nucleic acid CDMO market and the increasing number of projects for global pharmaceutical companies.
The 2nd Oligo Building was constructed by Aben General Construction, a company specializing in cGMP (current Good Manufacturing Practice) facilities. The building spans approximately 3,300 pyeong (10,900 square meters), stands 60 meters tall, and consists of nine floors. Unlike the 1st Oligo Building, which primarily houses large-scale production lines, the 2nd Oligo Building features a diverse range of lines from small and medium to large scale. This is a strategic move to meet the varied demands of clients, from early clinical stages to commercialization. Additionally, the top two floors have been designated as a “Future area” to allow for flexible responses to client requests.
The 2nd Oligo Building is equipped with an automated Process Control System (PCS) for process manufacturing equipment, a Building Management System (BMS) for controlling non-process facilities such as temperature, humidity, and differential pressure, and a Warehouse Management System (WMS) for warehouse operations. These systems are designed to improve productivity and reduce costs.
In line with the recent global standards of ESG (Environment, Social, Governance), the company has implemented sustainable management policies such as reusing waste heat for heating, introducing a distillation system that operates without cooling water, and adopting new technologies to extend filter life.
With the completion of the 2nd Oligo Building, ST Pharm plans to further strengthen its three core business areas: oligonucleotide nucleic acid CDMO, production of small molecule synthetic drug substances, and mRNA therapeutic production utilizing its proprietary platforms (Smart Cap and STLNP).
Sung Mooje, CEO of ST Pharm, stated, “With the completion of the 2nd Oligo Building, ST Pharm will further enhance its customer-centric mindset to respond more closely to the diverse needs of the market. Based on our spirit of ‘Gaesin Changrae’ (Opening New Paths to Create the Future), all our employees will strive to become an innovative company that saves lives.”
Meanwhile, the completion ceremony was attended by Kang Jungseok, Chairman of the Dong-A Socio Committee; Sung Mooje, President of ST Pharm; Kim Minyoung, President of Dong-A Socio Holdings; Jung Jaehoon, President of Dong-A ST; Baek Sanghwan, President of Dong-A Pharmaceutical; Park Yooni, President of Aben General Construction; as well as executives from overseas client companies, adding prestige to the event.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
